Join MitoAction and Dr. Alex Dorenbaum, Chief Medical Officer at Reneo Pharmaceuticals, as they discuss the Stride Study results for mavodelpar in Primary Mitochondria Myopathy. This will be a roundtable discussion format so patients and clinicians can ask their questions.
